诺诚健华 (上交所代码:688428;香港联交所代码:09969)今日宣布,其自主研发的新型BTK(布鲁顿酪氨酸激酶)抑制剂奥布替尼(商品名:宜诺凯)已获得中国国家药品监督管理局(NMPA)的批准,用于一线治疗慢性淋巴细胞白血病/小淋巴细胞淋巴瘤(CLL/SLL)。此次批准标志着奥布替尼在CLL/SLL治疗领域的重大突破,将为更多淋巴瘤患者带来一线治疗的新选择。在此之前,奥布替尼已在中国获得批准,...
Source Link诺诚健华 (上交所代码:688428;香港联交所代码:09969)今日宣布,其自主研发的新型BTK(布鲁顿酪氨酸激酶)抑制剂奥布替尼(商品名:宜诺凯)已获得中国国家药品监督管理局(NMPA)的批准,用于一线治疗慢性淋巴细胞白血病/小淋巴细胞淋巴瘤(CLL/SLL)。此次批准标志着奥布替尼在CLL/SLL治疗领域的重大突破,将为更多淋巴瘤患者带来一线治疗的新选择。在此之前,奥布替尼已在中国获得批准,...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.